Striatal Distribution of Dopamine Transporters and Dopamine D2 Receptors at Different Stages of Parkinson's Disease
Striatal Distribution of Dopamine Transporters and Dopamine D2 Receptors at Different Stages of Parkinson's Disease
复制标题
帕金森病不同阶段多巴胺转运蛋白和多巴胺D2受体的纹状体分布
DOI：
10.1177/197140091102400211
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
K. Ishiwata
中科院分区：
文献类型：
--
作者：
M. Mishina;K. Ishii;M. Suzuki;S. Kitamura;K. Ishibashi;M. Sakata;K. Oda;M. Hamamoto;S. Kominami;S. Kobayashi;Y. Katayama;K. Ishiwata
我们使用正电子发射断层扫描（PET）、多巴胺转运蛋白（DAT）的[11C]2β-甲氧基-3β-（4-氟苯基）托烷（CFT）和多巴胺D2受体（D2R）的[11C]雷氯必利（RAC）研究了帕金森病（PD）纹状体在不同阶段的变化。我们研究了 8 名老年健康志愿者（A 组）、13 名未接受药物治疗的 PD 患者（B 组）和 7 名患有轻度运动障碍的晚期 PD 患者（D 组）。 B组6名患者在抗帕金森病治疗后重新检查（C组）。感兴趣的区域被绘制在 PET 图像中的小脑半球、尾状核头部 (CN) 以及前壳核 (AP) 和后壳核 (PP) 上。我们计算了摄取比率指数（URI）、不对称指数（AI）和突触前与突触后比率（PPR）来评估多巴胺能功能。 3个PD组的DAT均小于A组。B组PP中RAC的URI显着大于A组和C组。PD组壳核中CFT的AI大于正常人，PP中RAC的AI在B组中最大。3个PD组中AP和PP的PPR均小于A组。PD患者中DAT随着疾病进展而降低。 RAC 的结合在未接受药物治疗的 PD 患者的壳核中最大，但由于 RAC 的 D2R 亲和力较弱，因此在治疗的 PD 患者中无法检测到增强的结合。
We investigated the alteration of dopaminergic system in striata of Parkinson's disease (PD) at different stages using positron emission tomography (PET), [11C]2β-carbomethoxy-3β-(4-fluorophenyl)tropane (CFT) for dopamine transporter (DAT), and [11C]raclopride (RAC) for dopamine D2 receptor (D2R). We studied eight elderly healthy volunteers (Group A), 13 drug naïve patients with PD (Group B), and seven advanced PD patients with mild dyskinesia (Group D). Six patients in Group B were re-examined after antiparkinsonian therapy (Group C). Regions of interest were drawn on the cerebellar hemisphere, head of the caudate nucleus (CN), and anterior (AP) and posterior putamen (PP) in the PET images. We calculated uptake ratio index (URI), asymmetry index (AI) and presynapse-to-postsynapse ratio (PPR) to evaluate dopaminergic function. DAT was smaller in the three PD groups than the Group A. URI of RAC in the PP was significantly larger in Group B than in Groups A and C. AI of CFT in the putamen was larger in the PD groups than in normal subjects, and AI of RAC in the PP was the largest in the Group B. PPRs in the AP and PP were smaller in the three PD groups than in Group A. DAT decreased with disease progression in patients with PD. Binding of RAC was largest in the putamen of drug-naïve PD patients, but the enhanced binding could not be detected in the therapeutic patients with PD because of weak D2R affinity of RAC.